BIOAFFINITY TECHNOLOGIES, INC. Financials bioAffinity Technologies, Inc.
Equities
BIAF
US09076W1099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.53 USD | +6.75% |
|
-15.67% | +72.05% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 13.39 | 13.97 |
| Enterprise Value (EV) 1 | 2.23 | 12.73 |
| P/E ratio | -0.88 x | -1.62 x |
| Yield | - | - |
| Capitalization / Revenue | 2,788,174,058 x | 5,517,494 x |
| EV / Revenue | 464,207,162 x | 5,026,702 x |
| EV / EBITDA | -0.56 x | -1.68 x |
| EV / FCF | -653,054 x | -3,531,083 x |
| FCF Yield | -0% | -0% |
| Price to Book | 1.21 x | 2.85 x |
| Nbr of stocks (in thousands) | 8,370 | 9,502 |
| Reference price 2 | 1.600 | 1.470 |
| Announcement Date | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | 0.004803 | 2.532 |
| EBITDA 1 | -2.582 | -2.202 | -4.001 | -7.595 |
| EBIT 1 | -2.604 | -2.207 | -4.011 | -7.973 |
| Operating Margin | - | - | -83,511.51% | -314.84% |
| Earnings before Tax (EBT) 1 | -7.266 | -6.324 | -8.152 | -7.916 |
| Net income 1 | -7.269 | -6.326 | -8.154 | -7.937 |
| Net margin | - | - | -169,771.25% | -313.41% |
| EPS 2 | -2.717 | -2.365 | -1.812 | -0.9073 |
| Free Cash Flow | - | -0.8592 | -3.414 | -3.605 |
| FCF margin | - | - | -71,082.53% | -142.36% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/25/22 | 4/25/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 9.92 | 10 | - | - |
| Net Cash position 1 | - | - | 11.2 | 1.24 |
| Leverage (Debt/EBITDA) | -3.843 x | -4.543 x | - | - |
| Free Cash Flow | - | -0.86 | -3.41 | -3.61 |
| ROE (net income / shareholders' equity) | - | 55.6% | 2,320% | -99.8% |
| ROA (Net income/ Total Assets) | - | -173% | -36.8% | -48.8% |
| Assets 1 | - | 3.667 | 22.18 | 16.25 |
| Book Value Per Share 2 | -5.630 | -5.900 | 1.320 | 0.5200 |
| Cash Flow per Share 2 | 0.0300 | 0.5100 | 1.360 | 0.3000 |
| Capex 1 | 0 | - | 0.22 | 0.02 |
| Capex / Sales | - | - | 4,580.2% | 0.9% |
| Announcement Date | 4/25/22 | 4/25/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +72.05% | 27.29M | |
| +1.69% | 12.8B | |
| -7.57% | 7.61B | |
| +3.22% | 5.41B | |
| +0.93% | 4.51B | |
| +8.48% | 4.49B | |
| +9.21% | 2.73B | |
| -13.87% | 2.02B | |
| -11.63% | 1.73B | |
| +3.45% | 1.64B |
- Stock Market
- Equities
- BIAF Stock
- Financials bioAffinity Technologies, Inc.
